Latest news
Analyst Matt Phipps Maintains Buy on NewAmsterdam as PREVAIL Interim Design Bolsters Cardiovascular Efficacy Odds and Risk-Reward Profile - TipRanksTipRanks · Thu, 06 Aug 2026 23:36:05 GMTMatt Phipps Reiterates Buy on Insmed as Brinsupri Outperformance, Raised Guidance and Higher Peak Sales Outlook Strengthen Long-Term Growth Story - TipRanksTipRanks · Thu, 06 Aug 2026 18:36:05 GMT